Siemens Healthineers AG J.P. Morgan Healthcare Conference, January 13, 2026 Unrestricted © Siemens Healthineers, 2026 Unrestricted © Siemens Healthineers, 2025 This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context. This webcast serves for information purposes only and the information contained ...

These statements are subject to risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements, including risks related to changes in the competitive environment; market demand and pricing pressure; cost containment measures that could adversely affect the price of or demand for our products; raw material, energy, and other input costs; supply chain disruptions (including availability of drugs used in our Surgical Pain and Recovery product ...

Core Insights - Align Technology, Inc. has launched a new initiative in collaboration with the Canadian Foundation for the Advancement of Orthodontics (CFAO) to support Invisalign treatment for 30 eligible patients [1] Company Overview - Align Technology is a leading global medical device company specializing in the design, manufacture, and sale of the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Group 1 - The presentation is led by Ivan Tornos, who is the President, CEO, and Chairman of the Board of Zimmer Biomet [1] - The company aims to summarize its presentation quickly to accommodate the busy schedule of the audience, which includes numerous presentations over the next few days [2] - Zimmer Biomet expresses satisfaction with the progress made over the last five years, indicating a positive outlook for the company in 2026 [3]

J.P. Morgan 44th Annual Healthcare Conference failure to retain key suppliers; challenges to the future development of our non-insulin drug delivery product line; our failure or that of our contract manufacturer or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations or other manufacturing difficulties; extensive government regulation applicable to medical devices, as well as complex and evolving privacy and data protection laws; our use of artificial intelli ...

Core Viewpoint - SciSparc Ltd. announced a definitive agreement to acquire a portfolio of medical endoscopy patents, aiming to expand its presence in the medical device sector and accelerate commercialization plans [1][2][3]. Group 1: Acquisition Details - The acquisition includes patents, trademarks, and related rights associated with endoscopic systems and medical cameras, specifically the MUSE endoscopic system designed for minimally invasive procedures [2]. - The company plans to issue ordinary shares to the seller at closing, which will represent approximately 19.99% of the company's outstanding stock [4]. - SciSparc may opt to issue pre-funded warrants instead of some shares at its discretion [5]. Group 2: Commercial Strategy - SciSparc intends to commercialize the acquired technologies immediately after the deal closes, aiming to replicate existing successful distribution models [4]. - The company plans to leverage licensing and regional partnerships to expand its market reach in North America, Europe, and Latin America [4]. Group 3: Closing Conditions and Market Outlook - The acquisition is subject to customary conditions, including regulatory approvals, with an expected closing date by March 8, 2026 [6]. - A market research report indicates growth in the global GERD device market, driven by demand for innovative endoscopy systems, which may help SciSparc extend its reach into new medical segments alongside its pharmaceutical initiatives [6]. Group 4: Stock Performance - Following the announcement, SciSparc shares were trading lower by 12.07% to $1.27 [7].

Philadelphia, Pennsylvania--(Newsfile Corp. - January 13, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Integer securities during the Class Period may, no ...

Core Insights - Spineway achieved a full-year revenue of €12.4 million in 2025, reflecting a 4% increase compared to 2024, despite facing challenges such as postponed approvals in Latin America and delays in Asia [4] - The company experienced a significant acceleration in sales during Q4 2025, with revenue reaching €3.8 million, marking a 34% increase from Q4 2024 [3] Revenue Breakdown - H1 revenue for 2025 was €5.573 million, down 15% from €6.535 million in 2024 [2] - H2 revenue for 2025 was €6.857 million, up 27% from €5.415 million in 2024 [2] - The total revenue for 2025 was €12.430 million, compared to €11.950 million in 2024 [2] Market Performance - The growth in Q4 2025 was attributed to an increase in sales across all markets and the fulfillment of key account orders that were deferred from the first half of the year [3] - The geographical diversification of Spineway, particularly in Asia and Latin America, contributed positively to its performance, allowing the company to enter new countries [4] Future Outlook - Spineway plans to obtain new approvals in 2026 for its premium product ranges in Latin America and Asia, aligning with its commercial development strategy [5] - The company aims to leverage its strong commercial momentum and diversified geographical presence to solidify its position as a major player in spine surgery [5]

Core Insights - Medtronic is positioning itself for growth in key markets such as pulsed-field ablation (PFA) and renal denervation, which are expected to become multi-billion-dollar opportunities [1] Market Position - Medtronic holds the second-largest market share in the PFA market, following Boston Scientific, and has been gaining market share over the past two years [2] - The company currently leads the renal denervation market with its Symplicity product lines and benefits from a favorable competitive landscape [5] Research and Development - Medtronic allocates 8.5% of its revenue to R&D, with plans to increase this to 10% to accelerate innovation and maintain technological leadership [3] Growth Opportunities - Renal denervation is identified as a significant growth opportunity, addressing the issue of hypertension management where approximately 50% of patients discontinue medication within a year [4] - The focus on innovation in renal denervation is expected to yield strong financial returns and enhance the company's reputation in addressing unmet health needs [7] Product Development - The Hugo surgical robot has been approved for urology, with over 500 doctors trained, indicating a strategic focus on physician impressions and usability in surgical procedures [6]